Comparison of optic nerve head topography and retinal nerve fiber layer in eyes with narrow angles versus eyes from a normal open angle cohort - a pilot study.

Purpose: To compare the optic nerve head (ONH) and retinal nerve fiber layer (RNFL) in eyes with narrow angles and normal intraocular pressure (IOP) to normal control eyes.

Materials And Methods: A total of 70 eyes of 52 subjects with narrow angles and 40 eyes of 34 normal subjects were enrolled. Narrow angle eyes were defined as the following: (i) the pigmented trabecular meshwork was not visible for ≥ 180° on gonioscopy, (ii) untreated IOP ≤ 21 mmHg, (iii) no peripheral anterior synechiae (PAS) was observed, and (iv) optic discs were without glaucomatous changes, defined as neuroretinal rim thinning, focal notching, disc hemorrhages, or focal RNFL defects.

Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients.

Background And Purpose: Brinzolamide is a new topical carbonic anhydrase inhibitor for intraocular pressure (IOP) control. It has high inhibitory activity against human carbonic anhydrase II, which is the key isoenzyme regulating aqueous humor production. We conducted this study to compare the ocular hypotensive effect and safety of 1% brinzolamide versus that of 0.

A six-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.i.d. to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d.

This was a 6-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.

Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma.

Two independent, prospective trials were recently conducted to assess the efficacy of latanoprost in reducing intraocular pressure (IOP) in patients with primary angle-closure glaucoma (PACG). The first study was a 2-week, randomized, double-masked comparison of latanoprost treatment and timolol treatment in patients with PACG. Patients were randomized to one of two parallel treatment groups, receiving either placebo in the morning and latanoprost 0.

The efficacy of brimonidine in preventing intraocular pressure elevation in the provocative test for primary angle-closure glaucoma.

The purpose of this study was to evaluate the efficacy of 0.2% brimonidine tartrate in preventing intraocular pressure (IOP) elevation in the dark-prone provocative test for primary angle-closure glaucoma (PACG). Twenty-two eyes from 22 patients with angle-closure glaucoma were enrolled in this study.